key: cord-0776971-djmcmxlk
authors: Bafna, Khushboo; White, Kris; Harish, Balasubramanian; Rosales, Romel; Ramelot, Theresa A.; Acton, Thomas B.; Moreno, Elena; Kehrer, Thomas; Miorin, Lisa; Royer, Catherine A.; García-Sastre, Adolfo; Krug, Robert M.; Montelione, Gaetano T.
title: Hepatitis C Virus Drugs That Inhibit the SARS-CoV-2 Papain-Like Protease Synergize with Remdesivir to Suppress Viral Replication in Cell Culture
date: 2021-04-27
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109133
sha: f0fc2192357f54cf57065e8985775bf77ff0a2d7
doc_id: 776971
cord_uid: djmcmxlk

Effective control of COVID-19 requires antivirals directed against SARS-CoV-2. We assessed ten hepatitis C virus (HCV) protease-inhibitor drugs as potential SARS-CoV-2 antivirals. There is a striking structural similarity of the substrate binding clefts of SARS-CoV-2 main protease (Mpro) and HCV NS3/4A protease. Virtual docking experiments show that these HCV drugs can potentially bind into the Mpro binding cleft. We show that seven HCV drugs inhibit both SARS-CoV-2 Mpro protease activity and SARS-CoV-2 virus replication in Vero and/or human cells. However, their Mpro inhibiting activities did not correlate with their antiviral activities. This conundrum was resolved by demonstrating that four HCV protease inhibitor drugs, simeprevir, vaniprevir, paritaprevir, and grazoprevir inhibit the SARS CoV-2 papain-like protease (PLpro). HCV drugs that inhibit PLpro synergize with the viral polymerase inhibitor remdesivir to inhibit virus replication, increasing remdesivir’s antiviral activity as much as 10-fold, while those that only inhibit Mpro do not synergize with remdesivir.

Effective control of the SARS-CoV-2 coronavirus that causes COVID-19 requires 17 antivirals. Considering the urgency to identify effective antiviral drugs, and the usually 18 lengthy process involved in approving candidate drugs for human use, our goal is to 19 identify existing drugs already approved for use in humans that can be repurposed as 20 safe and effective therapeutics for treating COVID-19 infections, and which may also be 21 useful as lead molecules for novel drug development. 22 J o u r n a l P r e -p r o o f expressing the SARS-CoV-2 ACE2 receptor. Surprisingly, we found that four HCV 1 drugs also inhibit PL pro protease activity (including one that did not inhibit M pro ). 2

Consequently, HCV drugs that inhibit M pro and/or PL pro can suppress SARS-CoV-2 virus 3 replication, viz, boceprevir (BOC), narlaprevir (NAR), vaniprevir (VAN), telaprevir (TEL), 4 paritaprevir (PAR), simeprevir (SIM), grazoprevir (GRZ), and asunaprevir (ASU). 5

Further, we demonstrate that the four HCV drugs which inhibit the proteolytic 6 activity of PL pro , SIM, GRZ, PAR, and VAN, also act synergistically with remdesivir to 7 inhibit SARS-CoV-2 virus replication, thereby increasing remdesivir antiviral activity as 8 much as 10-fold. In addition, the PL pro -specific inhibitor, GRL0617, also synergizes with 9

remdesivir. In contrast, the HCV drugs BOC and NAR, which inhibit M pro but not PL pro , 10 as well as the M pro -specific inhibitor GC-376, act additively, rather than synergistically 11 with remdesivir to inhibit virus replication. Our results suggest that the combination of a 12 HCV protease inhibitor with a RNA polymerase inhibitor could potentially function as an 13 antiviral against SARS-CoV-2. More generally, our results strongly motivate further 14 studies of the potential use of PL pro protease inhibitors in combination with RNA 15 polymerase inhibitors as antivirals against SARS-CoV-2. 16 ( Figure 1E ). In contrast, little or no inhibition activity was detected in this FRET assay 1 with the other seven HCV protease inhibitors (Supplementary Figure S3 A 

We also developed a 1D 1 H-NMR assay, using the peptide substrate 3 KTSAVLQ/SGFRKME that lacks the Dabsyl and Edans N-terminal and C-terminal tags 4 (Supplementary Figure S4) . In this 1D 1 H-NMR assay, NAR, BOC, and TEL have 5 substantial enzyme inhibition activity, as was the case in the FRET assay. In addition, in 6 the NMR assay substantial inhibitory activity was also observed for VAN 

The motivation for the docking and biophysical studies described above was to 16 identify HCV drugs with the potential to inhibit SARS-CoV-2 virus replication. For 17 antiviral assays, Vero E6 cells or human 293T cells expressing the ACE2 receptor, were 18 grown in 96-well plates, and were incubated with various levels of a HCV protease 19 inhibitor for 2 hours. Cells were then infected with SARS-CoV-2 virus at the indicated 20 multiplicity of infection [moi, plaque-forming units (pfu)/cell], and incubated for the 21 indicated times at 37 0 C in the presence of the inhibitor. Virus-infected cells were 22 identified by immunofluorescence using an antibody specific for the viral nucleoprotein. 1

Inhibition of viral replication was quantified by determining the percentage of positive 2 infected cells at the end of the incubation period in the presence of the compound, as 3 compared with the number of infected cells in its absence. To determine whether a HCV 4 drug was cytotoxic, uninfected Vero E6 or human 293T cells were incubated with the 5 same levels of the compounds for the same length of time, and cytotoxicity was 6 measured using an MTT assay (Roche). In all of these replication assays, remdesivir 7 was used as a positive control. 8

Viral replication inhibition data in Vero E6 cells are summarized in Figure 2 and 9

Supplementary Table S2. Five of the HCV protease inhibitors tested, PAR, NAR, GRZ, 10 ASU, and BOC, inhibited SARS-CoV-2 virus replication at concentrations significantly 11 lower than the concentrations that cause cytotoxicity. Two other HCV protease 12 inhibitors, SIM and VAN, inhibited virus replication with low IC 50 values, but some 13 cytotoxicity was also observed. These seven HCV drugs have IC 50 values for inhibiting 14 SARS-CoV-2 replication of 4.2 to 19.6 µM. The remaining three HCV drugs tested, TEL, 15 GLE, and DAN, did not inhibit virus replication in Vero E6 cells, even at a drug 16 concentration of 50 µM. 17

Next, we also determined whether the HCV drugs exhibited similar antiviral 18 activities in human cells, specifically human 293T cells expressing the ACE2 receptor 19 (Figure 3 and Supplementary Table S2) IC 50 values ranging from 0.55 to 20.5 µM. GLE and DAN did not inhibit virus replication 5 in human cells, as was also the case in Vero cells. ASU, a modest inhibitor in Vero 6 cells, did not inhibit viral replication in human cells at concentrations lower than those 7 exhibiting cytotoxicity. 8

We also determined whether the inhibition of SARS-CoV-2 replication by 9

representative HCV protease inhibitors occurs at steps after virus entry, as would be 10 expected for inhibitors of viral proteases that are produced after infection. Accordingly, 11

we performed time of addition assays in human cells, using BOC (50 µM), GRZ (25 12 µM), NAR (50 µM), VAN (5 µM), and SIM (5 µM), concentrations that do not show 13 detectable cytotoxicity as measured by MTT assay (Supplementary Table S2) Simeprevir and grazoprevir synergize with remdesivir to increase inhibition of 4

Because M pro and PL pro generate either the RNA polymerase itself, or the 6 proteins that constitute the replication organelles required for polymerase function, we 7 predicted that HCV drugs that inhibit one or both of these viral proteases might be 8 synergistic with inhibitors of the viral polymerase like remdesivir. To test this hypothesis, 9

we carried out antiviral combination assays of SIM, GRZ, and BOC, respectively, with 10 remdesivir in Vero cells. To assess synergy, two analyses are required. In one analysis 11 the IC 90 of the remdesivir was measured in the presence of increasing concentrations of 12 each of these three HCV drugs (Figure 4 A-C). These results demonstrate that SIM and 13 GRZ increase the antiviral activity of remdesivir. For example, in the presence of 1.25 14 µM SIM, approximately 10-fold less remdesivir is required for the same antiviral effect 15 achieved in the absence of SIM (Figure 4 A) . A similar 10-fold enhancement in antiviral 16 activity of remdesivir is observed in the presence of GRZ, though at higher (6.25 µM) 17 GRZ concentrations ( Figure 4B) . Surprisingly, although BOC is a much better inhibitor 18 of M pro than either SIM or GRZ, BOC did not significantly affect the antiviral activity of 19 remdesivir ( Figure 4C ). In the second analysis, the IC 90 concentration of each HCV drug These combination antiviral assays indicate that SIM and GRZ, but not BOC, act 4 synergistically with remdesivir to inhibit virus replication. As confirmation, we subjected 5 these results to analysis by the Zero Interaction Potency (ZIP) model for synergy 6 (Ianevski et al., 2020). In the landscapes generated by this model ( Figure 4G -I), red 7 denotes a synergistic interaction, and green denotes an additive interaction. In this 8 model a synergistic interaction between drugs has a score greater than +10; an additive 9

interaction has a score between -10 to +10; and an antagonistic interaction has a score 10 of less than -10. The landscapes for the interaction of remdesivir with both SIM and 11 GRZ are red, with synergy scores of +30.2 and +25.0, respectively, denoting moderate 12 synergism. In contrast, the landscape for the interaction of remdesivir with BOC does 13 not indicate synergy ( Figure 4I ); the synergy score, -7.6, indicates an additive 14 interaction. We also carried out combination antiviral assays in human 293T cells. The 15 interaction between remdesivir and GRZ in inhibiting virus replication in the human cells 16 was also synergistic, with a red landscape and a synergy score of +20.3 17 Figure S5) . Consequently, at least two HCV drugs, SIM and GRZ, act 18 synergistically with remdesivir to inhibit SARS-CoV-2 virus replication in Vero and/or 19 human 293T cells. 20

Four HCV protease inhibitors that are synergistic with remdesivir inhibit PL pro 22

The preceding results demonstrate that several HCV inhibitors inhibit viral 1 replication, and that for some of these drugs inhibition is synergistic with the viral 2 replication inhibition activity of remdesivir. Most of these drugs also inhibit SARS-CoV-2 3 M pro . However, M pro and SARS-CoV-2 inhibition by these drugs were not consistently 4 correlated. For example, PAR does not inhibit M pro in either the FRET or NMR assay but 5

is an effective inhibitor of SARS-CoV-2 in both Vero (IC 50 = 6 µM) and 293T (IC 50 = 0.55 6 µM) assays. In addition, the HCV protease inhibitors SIM and GRZ, which are only 7 moderate inhibitors of M pro , synergize with remdesivir, while BOC, which is an excellent 8

inhibitor of M pro , acts additively rather than synergistically with remdesivir to inhibit virus 9

replication. Although the lack of strong correlation between protease inhibition activity 10 and viral inhibition activity could result from various effects, including the efficiency of 11 transport of drugs into the cell and/or metabolism of the drugs in the cell-based assays, 12 these results suggested that there might be a second viral target for some of these HCV 13 drugs, for which inhibition may provide the basis for the observed synergy. 14 Aside from both being Cys proteases, the active site of PL pro does not share 15 structural similarity with the HCV NS3/4A or M pro proteases. However, it has recently 16 been reported that SIM, GRZ, and ASU inhibit PL pro (Anson et al., 2020). Accordingly, 17

we carried out virtual docking studies of these same ten HCV drugs into the substrate 18 binding cleft of PL pro , using protocols similar to those developed in virtual docking 19 studies with M pro . The known PL pro inhibitor GRL0617 (Fu and Huang, 2020), was used 20 to assess the docking protocol, providing a reference AutoDock score of -7.54 kcal/mol. 21

The scores of docking poses for HCV drugs, summarized in Figure 5A and 22

Supplementary Table S1, range from -5.56 kcal/mol for BOC and NAR, to much more 23 favorable values of < -8 kcal/mol for others, including VAN, GRZ, SIM, and PAR. 1

These proof-of-concept docking studies suggest that, surprisingly, some HCV protease 2 inhibitors may bind in the active sites of both M pro and PL pro . 3

Based on these docking predictions, we anticipated that several HCV protease 4 inhibitors, not including BOC, NAR, or TEL, might effectively inhibit PL pro protease 5 activity. To test this hypothesis, fluorescence assays of PL pro inhibition were carried out, and PL pro , while PAR inhibits PL pro , but not M pro . Under these assay conditions, VAN 12 and SIM are more effective PL pro inhibitors than GRZ or PAR. 13

These results strengthened our hypothesis that synergy between these HCV 14 drugs and remdesivir arises primarily from their activities in inhibiting PL pro , rather than 15 from inhibiting M pro . To further test this, combination assays with remdesivir were carried 16 out also for NAR, PAR, and VAN. As predicted, PAR which moderately inhibits PL pro but 17 not M pro , is synergistic with remdesivir ( Figure 5C , synergy score +17.3). VAN, which 18 inhibits both M pro and PL pro , is also modestly synergistic, with synergy score + 10.9, 19

while NAR which inhibits M pro but not PL pro is additive with synergy score -3.6 (Figures 20

Data for HCV protease drugs on SARS-CoV-2 protease inhibition and synergy 1 are summarized in Figure 6A and in Supplementary Table S2 . Two drugs, BOC and 2 NAR, which are relatively good inhibitors of M pro but do not inhibit PL pro , have additive 3 interactions with remdesivir. Three drugs, GRZ, SIM, VAN which inhibit both M pro and 4 PL pro are synergistic, with synergy scores of +10.9 to +30.2. Interestingly, among these 5 three, VAN, which is a relatively strong inhibitor of both M pro and PL pro , has the weakest 6 synergy. A fourth HCV drug, PAR, which inhibits PL pro but not M pro , also has synergy 7 with remdesivir, with synergy score +17.3. These data demonstrate a correlation 8 between the PL pro inhibiting activities of these drugs and their ability to function 9

synergistically with remdesivir to suppress viral replication. 10

In order to further test this model of synergy, we also carried out biochemical and has been reported to be specific for M pro relative to PL pro (Sacco et al., 2020), the 15 relative specificity of GLR0617 (or compound 6) for PL pro relative to M pro has not 16 previously been reported. Using the same fluorescence assays outlined above, we 17 validated the high specificity of GC-376 for M pro inhibition compared to PL pro ( Figure 6B D; synergy score +18.6). We conclude that inhibitors of the SARS-CoV-2 PL pro protease 23 function synergistically with remdesivir to inhibit viral replication, whereas specific 1 inhibitors of the M pro protease act additively with remdesivir. To provide antiviral drugs that can be rapidly deployed to combat the COVID-19 5 pandemic, we carried out the present study to identify currently available drugs that 6 could potentially be repurposed as inhibitors of the SARS-CoV-2 virus that causes the 7 COVID-19 disease. A total of eight HCV drugs were identified that inhibit virus 8 replication in Vero and/or human 293T cells expressing the ACE2 receptor. 9

We initiated our search based on the striking similarity of the substrate binding assay for M pro inhibition, which confirmed that BOC, NAR, and TEL inhibit M pro . In the 16 NMR assay VAN also has inhibitory activity comparable to TEL, while GRZ, SIM, and 17

ASU are moderate inhibitors of M pro . The ability of the NMR assay to detect inhibitory 18 activity that was not detected by the FRET assay is attributable to several factors, 19

including differences in substrate and enzyme concentrations used in these assays, and 20 differences in the substrates themselves. The ability of HCV drugs to inhibit M pro also 21 depends on other details of the assay conditions, most notably the enzyme, substrate, Although the active site of PL pro does not share structural similarity with the HCV 1 NS3/4A protease, we observe that four HCV drugs, SIM, GRZ, VAN, and PAR inhibit 2 PL pro protease activity in vitro. None of these four inhibitors can form covalent bonds 3 with the active-site Cys residue of PL pro . VAN is a good inhibitor of both M pro and PL pro , 4

presumably accounting for its strong inhibition of virus replication. All four of these HCV 5 drugs function synergistically with remdesivir to inhibit SARS-CoV-2 virus replication in 6

Vero and/or human cells. 7

Particularly interesting in this set is PAR, which has the strongest potency in the 8 human cell assay (IC 50 = 0.55 µM), strong synergy with remdesivir (synergy score + 9

17.3), and low cytotoxicity (CC 50 > 100 µM) in both the Vero and human cell assays 10 (Supplementary Table S2 ). However, PAR only moderately inhibits PL pro and does not 11 inhibit M pro . One possibility is that inhibition of virus replication by PAR could result, at 12 least in part, from its inhibition of a third target. Inhibition of such a putative third target 13 might also play some role in the inhibition of virus replication by the other HCV drugs. 14 In addition to inhibiting cleavage of PL pro viral polyproteins to generate crucial 15 viral proteins, PL pro also cleaves the ubiquitin-like ISG15 protein from viral proteins 16 Viral replication assays using combinations of drugs allowed us to assess 4 whether the interactions between HCV drugs and remdesivir are additive or synergistic. 5

We found that these inhibitory effects are additive or synergistic depending on which 6 HCV drug is used to inhibit virus replication. In particular, HCV drugs that inhibit PL pro 7 synergize with remdesivir to inhibit SARS-CoV-2 replication in Vero and 293T cells. 8

These HCV drugs include SIM, VAN, GRZ, and PAR. The conclusion that inhibition of 9 PL pro alone is sufficient for synergy with remdesivir was confirmed by a synergy assay 10 with compound 6 (a GRL0617 analog) that specifically inhibits PL pro but not M pro . On the 11 other hand, we show that the HCV drugs BOC and NAR that inhibit only M pro have an 12 additive rather than a synergistic interaction with remdesivir in inhibiting SARS-CoV-2 13

replication. The conclusion that selective inhibition of M pro has an additive interaction 14 with remdesivir was confirmed by a synergy assay with compound GC-376, that 15 specifically inhibits M pro but not PL pro . Another M pro inhibitor (PF-00835231) has been 16 reported to act in combination with remdesivir, but it was not clear whether this 17 interaction was additive or synergistic (Boras et al, 2020) . It was also recently reported 18 that SIM acts synergistically with remdesivir, but that this synergy results from inhibition 19 of M pro and/or other targets (Lo et al., 2020) . 20

The mechanism through which PL pro inhibition, but not M pro inhibition, results in 21 synergy with remdesivir is not yet known. One rational mechanism involves the critical orally-administered drugs that might also be combined with an oral polymerase inhibitor 10 rather than with remdesivir, which has to be administered intravenously. One such oral 11 

A provisional patent application related to these studies has been filed. GTM is a 4 founder of Nexomics Biosciences, Inc. The AG-S laboratory has received research 5 support from Pfizer, Senhwa Biosciences, 7Hills Pharma, Avimex, Blade Therapeutics, 6

Dynavax, ImmunityBio, Nanocomposix, Pharmamar, and Kenall Manufacturing, and 7 AG-S has consulting agreements for the following companies involving cash and/or 8 stock: Vivaldi Biosciences, Pagoda, Contrafect, 7Hills Pharma, Avimex, Vaxalto, 9

Accurius, Pfizer, and Esperovax. These relationships have no conflict of interest with 10 respect to this study. s.d., n = 3; NMR resonance ratio uncertainties were based on signal-to-noise 27 measurements. See also Tables S1, S2, S3, and Figs. S1, S2, S3, S4, S7. 28

Inhibition of viral replication was determined in a concentration-dependent matter in 30

Vero E6 cells. Replication assays were performed at moi of 0.025 pfu/cell. In all panels, 31 viral infectivity is shown as a solid line and cell toxicity as a dashed line. Data = mean ± 32 SD; n = 3 independent samples. The estimated IC 50 is labeled in the upper left corner of 33 each plot. Remdesivir is included as a standard of care control. See also Table S2 . 34 points before (-2 hrs), at (0 hrs), or after (+2 or +4 hrs) viral infection, at moi of 2 3 pfu/cell. Data is mean ± SD; n = 3 independent samples. See also Table S2 . landscapes and combination scores generated by the ZIP method using the program 9

SynergyFinder (Ianevski et al., 2020) . See also Table S2 and Fig. S5 . 10 inhibit PL pro , and is also not synergistic with remdesivir. See also Tables S2, S3 and  20 Figs. S1, S6. 21 Tables S1 and S2. Further information and requests for resources and reagents should be directed to and 4 will be fulfilled by the designated contact, Gaetano T. Montelione (monteg3@rpi.edu). 5 6

All materials generated in this study are available upon request. 8 9

The following datasets generated during this study are available at the BioMagResDB: 11 BioMagResDB accession number: 50568. Title: " 1 H and 15 N assignments for 14-12 residues peptide that is cleaved by SARS-CoV-2 M pro ." DOI: and penicillin/streptomycin (Corning) at 37 °C and 5% CO 2 . hACE2-293T cells were 5 generated for this study. Briefly, 293T cells were transduced with a lentiviral vector 6 expressing human ACE2. Puromycin resistant cells with hACE2 surface expression 7

were sorted after staining with AlexaFluor 647-conjugated goat anti-hACE2 antibodies. 8

Cells were then single-cell-cloned and screened for their ability to support SARS-CoV-2 9

replication. All cell lines used in this study were regularly screened for mycoplasma 10 contamination using the Universal Detection Kit (ATCC, 30-1012K). 11

(http://www.chemspider.com/) and DrugBank (https://www.drugbank.ca/). Protein and 1 ligand coordinates were prepared using AutoDockTools; polar hydrogens were added to 2 protein structures, and Gasteiger-Marsili empirical atomic partial charges were added to 3 ligands. Torsional degrees of freedom (dihedral angles) were identified for each ligand. 4

These data and parameters for each protein and ligand were saved as individual 5 PDBQT files. In these studies, ligand dihedral angles were allowed to vary (except 6

where stated otherwise), and all protein dihedral angles were kept rigid. The program 7

Autogrid (Sanner, 1999) was used to prepare affinity maps for all atom types in the Homogeneity was validated by SDS-PAGE (> 95% homogeneous), and the construct 10 was validated by MALDI-TOF mass spectrometry. The enzymatic activity of freshly 11 purified M pro was measured using Michealis Menten equation best fit values of K M and 12 V max ; these were 55.5 µM and 0.018 µM/sec, respectively. The calculated k cat was 1.80 13 sec -1 , and k cat /K M was 32,400 sec -1 M -1 . were prepared in 20 mM TRIS buffer, pH 8.0, containing 100 mM NaCl, 1 mM EDTA, 20 and 1 mM DTT, flash frozen in 50 µL aliquots, and stored at -80 deg. For enzyme 21 assays, freshly thawed enzyme aliquots were prepared in buffers containing 3 mM 22 TCEP, and assayed for specific activity at the beginning and end of the data collection 23 session, or back-to-back with each measurement, in order to avoid spurious results due 1 to enzyme inactivation during a measurement session. 2 3

The proteolysis of substrate KTSAVLQ/SGFRKME was studied using 5

Fluorescence Resonance Energy Transfer (FRET) and nuclear magnetic resonance 6 (NMR) assays. Fluorescence studies were carried out using an Infinite M1000 TECAN 7 plate reader, with 3 mm path lengths, and Magellan TM software. NMR assays were 8 carried out using a Bruker Avance II 600 MHz NMR spectrometer system. For the FRET 9 assay the substrate was Dabsyl-KTSAVLQ/SGFRKME-Edans, labeled with a Dabcyl 10 and Edans FRET pair on the N and C-termini of the peptide, respectively, as described 11

elsewhere (Ma et al., 2020) . The NMR assay used the same peptide substrate without 12 the fluorescence dyes attached. Both labeled and unlabeled peptide substrates were 13 obtained from GenScript USA, Inc. 14 15

As part of our initial development of the FRET assay for M pro activity, we 16 assessed catalysis rates over the range of 1 nM to 200 nM enzyme concentration, with 17 the fluorophore-labeled peptide substrate. We observed significant proteolytic activity 18 over this whole range (Supplementary Figure S2 

Docking and 1 chemoinformatic screens for new ligands and targets

Docking screens: right for the right reasons

Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-7 like protease

Simeprevir potently suppresses SARS-11

CoV-2 replication and synergizes with remdesivir. bioRxiv

Boceprevir, GC-376, and calpain inhibitors II, 15 XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

The Role of 18 Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and 19

Macrophage Activation Syndrome-Like Disease

Automated docking using a Lamarckian genetic algorithm and 23 an empirical binding free energy function

AutoDock4 and AutoDockTools4: Automated docking with 28 selective receptor flexibility

Structure of papain-like 32 protease from SARS-CoV-2 and its complexes with non-covalent inhibitors

Expression and Cleavage of Middle East Respiratory 36

Membrane Vesicles That Mimic Those Associated with Coronaviral RNA 38 Replication

Resistance outside the substrate envelope: hepatitis C NS3/4A protease 41 inhibitors

We used the free open source AutoDock suite (Morris et al., 2009) . AutoDockTools 15 (Sanner, 1999) was used for coordinate preparation, docking, and analysis of results. 16The computational docking program AutoDock v4.2. 6 . is based on an empirical free-17 energy force field and uses a search method based on Lamarckian genetic algorithm 18 (Morris et al., 1998) . Target protein coordinates were obtained from SARS-CoV-2 M pro 19 X-ray crystal structure (PDB id 6Y2G) (Zhang et al., 2020b), and structural water was 20 removed. Three-dimensional coordinates for ligand molecules were obtained from PDB 21 (http://www.rcsb.org/) or from chemical structure databases, ChemSpider 22For PL pro , inhibitor complexes in the PDB revealed that the BL2 loop present at 1 the entrance of active site adopts significantly different conformations depending on the 2 size of the inhibitor bound to the PL pro . This plasticity in the BL2 loop suggests an 3 induced fit mechanism of ligand binding to PL pro active site. To avoid a closed 4 conformation of the BL2 loop found in protein ligand complex we chose a SARS-CoV-2 5 PL pro X-ray crystal structure in its apo form (PDB id 6W9C) as the target to dock HCV 6 protease inhibitors. The docking protocol was same as above, except a larger grid of 7 size 56, 56, and 58 points in the x, y and z direction respectively was used to compute 8 electrostatic maps for PL pro target. For a comparative analysis, docking simulations of 9 PL pro inhibitor GRL0617 (PDB id 7CJM) were also performed using the same protocol. containing 20 mM HEPES pH 6.5, 120 mM NaCl, 0.4 mM EDTA and 3 mM TCEP. 22Additionally, 1 mg/mL BSA was added to the buffer for FRET assays. For the FRET 23 infected with 8000 PFU (moi of 2) of SARS-CoV-2, the drug was added at different 1 times relative to infection as indicated, and the infection was ended by fixation with 4% 2 formaldehyde after 8 hours of infection (single cycle assay).